In a prospective study, we conducted a 3-month clinical trial of the combination of CMP and UTP in 75 patients with diabetic neuropathy. The aim of this study was to evaluate the efficacy and safety of the combination of CMP and UTP in the treatment of diabetic neuropathy. Several preclinical studies have demonstrated the effect the combination of CMP and UTP in the regeneration of the myelin sheath and nerve cells. NUCLEO CMP FORTE ® is a combination of nucleotides (Cytidine 5'- Monophosphate Disodium and Uridine -5' Triphosphate Trisodium). There are numerous therapeutic methods, but most of them present a problem of efficacy and tolerance. Email: April 20, 2015ĭiabetic neuropathy is the earliest and most common chronic complication of diabetes. Lala Bouna Seck 1, Anna Basse 1, El Hachim Cissé 2, Demba Diedhiou 3, Kamadore Touré 1,4, Moustapha Ndiaye 1, Said Nourou Diop 4, Mouhamadou Mansour Ndiaye 1ġDepartment of Neurology, Fann University Teaching Hospital, Dakar-Senegal.ĢDepartment of Neurosurgery, Fann University teaching hospital, Dakar-Senegal.ģDepartment of Internal Medicine and Antidiabetes Center, Abass Ndao National Hospital, Dakar-Senegal.ĤDepartment of Health Sciences, University of Thies, Senegal.Ĭorresponding author. © International Scholars JournalsĮfficacy and tolerance of combination of Cytidine 5 ' monophosphate (CMP) and Uridine-5 ' Triphosphate Trisodium (UTP) in patients with diabetic neuropathy: results of a study conducted in Dakar-Senegal International Journal of Medicine and Medical Sciences ISSN 2167-0404 Vol. Efficacy and tolerance of combination of Cytidine 5 ' monophosphate (CMP) and Uridine-5 ' Triphosphate Trisodium (UTP) in patients with diabetic neuropathy: results of a study conducted in Dakar-Seneg
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |